KAE609 + Piperaquine Phosphate
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Plasmodium Falciparum Malaria
Conditions
Plasmodium Falciparum Malaria
Trial Timeline
Jul 1, 2015 → Sep 1, 2015
NCT ID
NCT02543086About KAE609 + Piperaquine Phosphate
KAE609 + Piperaquine Phosphate is a phase 1 stage product being developed by Novartis for Plasmodium Falciparum Malaria. The current trial status is terminated. This product is registered under clinical trial identifier NCT02543086. Target conditions include Plasmodium Falciparum Malaria.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02543086 | Phase 1 | Terminated |
Competing Products
13 competing products in Plasmodium Falciparum Malaria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KLU156 + Coartem | Novartis | Phase 3 | 77 |
| artemether:lumefantrine (2.5 mg:30 mg) | Novartis | Phase 2/3 | 65 |
| INE963 | Novartis | Phase 2 | 52 |
| KAE609 + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 52 |
| KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation | Novartis | Phase 2 | 52 |
| Artemether-lumefantrine | Novartis | Phase 3 | 77 |
| INE963 + KAE609 (Cipargamin) + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 52 |
| KAF156 + LUM-SDF + Coartem | Novartis | Phase 2 | 52 |
| Azithromycin/Chloroquine + Sulfadoxine-Pyrimethamine/Chloroquine | Pfizer | Phase 2/3 | 64 |
| Ferroquine (SSR97193) + Placebo + artesunate | Sanofi | Phase 2 | 51 |
| Ferroquine SSR97193 + Artefenomel | Sanofi | Phase 2 | 51 |
| Artefenomel (OZ439) + Ferroquine (SSR97193) | Sanofi | Phase 2 | 51 |
| Meplazumab for Injection + Sterile normal saline (0.9%) | Pacific Biosciences | Phase 1 | 25 |